Search results
Results From The WOW.Com Content Network
In patients taking drugs for cancer, the likelihood of MRONJ development varies from 0 - 12%. This again, varies with the type of cancer, although prostate cancer and multiple myeloma are reported to be at a higher risk. [8] In patients taking oral drugs for osteoporosis, the likelihood of MRONJ development varies from 0 - 0.2%. [7]
Denosumab, sold under the brand names Prolia among others, is a human monoclonal antibody used for the treatment of osteoporosis, treatment-induced bone loss, metastases to bone, and giant cell tumor of bone.
Denosumab is a bone anti-resorptive agent that can be used to treat hypercalcemia in patients with a contraindication to bisphosphonates such as severe kidney failure or allergy. Denosumab is a monoclonal antibody that inhibits osteoclasts. It acts by binding RANK ligand preventing it from activating osteoclasts via NFKB. [22]
The Food and Drug Administration has approved Amgen's (AMGN) osteoporosis drug denosumab for use by cancer patients with solid tumors whose disease has metastasized to their bones. The indication ...
For men with prostate cancer and bone metastases zoledronic acid (a bisphosphonate) and denosumab (a RANK-ligand-inhibitor) appear to be the most effective in preventing skeletal complications. [85] However these agents also seem to cause more frequent and severe adverse events, including kidney failure for treatment with zoledronic acid and ...
“There are more than 200 types of cancer, with lots of possible symptoms,” says Dr Julie Sharp, head of health and patient information at CRUK. “It’s impossible to know them all, which is ...
Prolia (denosumab) is an injectable medication that helps treat osteoporosis. Osteoporosis is a condition that causes the bones to become thin and weak, leading to a higher risk of fractures and ...
Non-small cell lung cancer, oesophageal cancer, uterine cervical cancer, head and neck cancer and urothelial cancer: Nephrotoxicity, myelosuppression and nausea and vomiting (30-90%). Oxaliplatin: IV: Reacts with DNA, inducing apoptosis, non-cell cycle specific. Colorectal cancer, oesophageal cancer and gastric cancer